Hemoglobin A1c Testing Market to Spike to $1.6 Billion by 2017
September 27, 2013 07:21 ET
|
Research and Markets
Dublin, Sept. 27, 2013 (GLOBE NEWSWIRE) -- Research and Markets
(http://www.researchandmarkets.com/research/3k6s99/hemoglobin_a1c)
has announced the addition of the "Hemoglobin
A1c...
HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders
March 26, 2009 12:54 ET
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - March 26, 2009) - HemaQuest Pharmaceuticals today announced that
it has received two orphan medicinal product designations from the European
Commission for its product...
HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug
December 09, 2008 12:01 ET
|
HemaQuest Pharmaceuticals
SAN FRANCISCO, CA--(Marketwire - December 9, 2008) - HemaQuest Pharmaceuticals announced
today the successful completion of Phase 1 clinical trials of HQK-1001, an
orally-administered therapeutic...
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
November 04, 2008 09:00 ET
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that
the U.S. Food and Drug Administration (FDA) has awarded the company orphan
drug designations for sickle...
HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders
January 17, 2008 09:00 ET
|
HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - January 17, 2008) - HemaQuest Pharmaceuticals, which received its
first round of venture financing three months ago, today announced that the
U.S. Food and Drug...
HemaQuest Announces $20M Series A Financing for Anemia Drug Development
November 01, 2007 10:30 ET
|
HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - November 1, 2007) - HemaQuest Pharmaceuticals, a new company
developing proprietary small molecule therapeutics to treat serious blood
disorders, today announced that it...